Thompson Matthew 4
4 · ENDOLOGIX INC /DE/ · Filed Jan 2, 2019
Insider Transaction Report
Form 4
Thompson Matthew
Chief Medical Officer
Transactions
- Award
Common Stock
2018-12-30+470,115→ 523,177 total - Award
Option to Purchase
2018-12-30$0.74/sh+225,621$167,975→ 225,621 totalExercise: $0.74From: 2019-12-30Exp: 2028-12-30→ Common Stock (225,621 underlying) - Disposition to Issuer
Common Stock
2018-12-30−15,000→ 53,062 total
Footnotes (3)
- [F1]Shares subject to this Form 4 were granted as part of a performance restricted stock unit granted May 31, 2017. All shares granted were forfeited as of March 13, 2018 due to the single performance milestone being deemed not achievable by the Company. This forfeiture was not previously reported to the Securities and Exchange Commission, as the number of shares was deemed immaterial by the issuer.
- [F2]The time-based restricted stock unit award shall vest in three equal annual installments on December 30, 2019, December 30, 2020 and December 30, 2021 and shall settle in shares of common stock on each of those dates.
- [F3]100% of the option award shall vest on December 30, 2019.